Non al co holic fatty liver dis ease (NAFLD) is di agnosed in a sig nifi cant pro por tion of coro nary ar tery dis ease and type 2 dia be tes pa tients, ex ac er bat ing the un der ly ing dis ease. It is fre quently as so ci ated with abdomi nal obesity, dia be tes mel li tus, ar te rial hy per ten sion, age over 45 years and the ra tio of trans ami nase ac tiv ity [10, 6]. Although this dis ease of ten comes across as ymp to matic, the pro gres sion of stea to sis to stea to he pa ti tis is found in almost half of cases and in not less than 1/6 of pa tients fi bro sis of liver de vel ops. It is also known that 72% of patients with coro nary heart dis ease com bined with type 2 dia be tes are di ag nosed with NAFLD [3, 4, 6] The prob lem of the de vel op ment and pro gres sion of NAFLD in ad di tion to coro nary heart dis ease and type 2 dia be tes mel li tus is one of the most im por tant and ur gent tasks of in ter nal medi cine, since it leads to the wors en ing of comor bid dis eases [1]. Pa tients with NAFLD are usu ally as ymp to matic, high val ues of liver en zyme tests be ing the most com mon find
Abstract:The article describes the pantoprazole healing effect on the gastroduodenal mucosa in patients with NSAID gastropathy. Two groups of patients were compared, depending on the treatment they have got group, which was taking 75 mg of enteric aspirin per day and the group, where pantoprazole has been added to aspirin in the usual dose. Mucosa assessment was studied using fibrogastroduodenoscopy and Lanza score. Also, the relationship between aggression factors that cause NSAID gastropathy and mucosal protection agents has been studied. It was proved that the pantoprazole influence reduces the ulcerative-erosive lesions amount. Stomach erosive lesions percentage decreased from 58.18% to 42.42%, stomach ulcers from 14.55% to 6.06%, duodenum erosive lesions decreased from 34.55% to 24.24%, duodenum ulcers deceased from 9.09% to 3.03%. A positive correlation between LTB4 and Lanza scale was checked after pantoprazole treatment, indicating an impact on the LTB4 reduction in ulcers healing in patients with NSAID gastropathy.
Abstract:The objective of this study was to investigate the pantoprazole and rebamipide efficiency on NSAIDs (nonsteroidal anti-inflammatory drugs)-gastropathy restoring and healing in patients with coronary heart disease, stable angina, who have been taking aspirin for a long time period. The study included three groups of patients according to the treatment they have got: ASA (acetylsalicylic acid) in the first group; ASA and pantoprazole in the second; ASA, pantoprazole and rebamipide in the third one. To obtain the results, endoscopic method and proinflammatory cytokines LTB4 and protective prostaglandin E2 determination in the blood were used. The research demonstrated no ulcer effects in the group of patients who were treated by rebamipide, and significantly fewer gastroduodenal erosions, in comparison to the group, where treatment contained ASA and pantoprazole. The LTB4 (leukotriene B4) level decreased in pantoprazole and rebamipide treatment groups, but the PGE2 (prostaglandin E2) level increased only after rebamipide therapy. Therefore, rebamipide should be included to the therapy for the better NSAIDs-gastropathy treatment, in reason of its good reparative and gastroprotective properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.